Sino Biopharmaceutical’s Acquisition of Softhale

Baker McKenzie advised C-Lab International Limited the deal, while McDermott Will & Emery advised Softhale N.V.

C-Lab International Limited, a wholly-owned subsidiary of Sino Biopharmaceutical Limited, completed the acquisition of SOFTHALE NV for USD 110 million and additional payments related to regulatory and commercial milestones.

Sino Biopharmaceutical is an innovative research and development driven pharmaceutical conglomerate in China.

Softhale is a privately-owned Belgian company focused on the development of products for the treatment of respiratory diseases.

The Baker McKenzie core team included Partner Derek Poon (Picture), Dr. Thorsten Seidel (M&A Partner, Berlin), Dominique Maes (Private Equity/M&A Partner, Brussels), Kim Stas (Private Equity/M&A Counsel, Brussels) and Bruno Schroé (Private Equity/M&A Associate, Brussels).

McDermott Will & Emery advised Softhale N.V. with partners Nadine Hartung and Stephan Rau and comprised partners Todd Finger, Nina Siewert, Steffen Woitz, counsel Jana Grieb and associate Robert Feind.

Involved fees earner: Dominique Maes – Baker McKenzie; Derek Poon – Baker McKenzie; Bruno Schroe – Baker McKenzie; Thorsten Seidel – Baker McKenzie; Kim Stas – Baker McKenzie; Robert Feind – McDermott Will & Emery; Todd Finger – McDermott Will & Emery; Jana Grieb – McDermott Will & Emery; Nadine Hartung – McDermott Will & Emery; Stephan Rau – McDermott Will & Emery; Nina Siewert – McDermott Will & Emery; Steffen Woitz – McDermott Will & Emery;

Law Firms: Baker McKenzie; McDermott Will & Emery;

Clients: C-Lab International Limited ; Softhale;

Author: Sonia Carcano